

**ASX Announcement**

1 May 2026

**Change of Company Secretary**

**Melbourne, Australia, 1 May 2026:** Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") is pleased to announce the appointment of Ms. Naomi Lawrie as Company Secretary, effective 1 May 2026, to replace Ms. Melanie Leydin following team reassignments at Vistra (Australia) Pty Ltd, the Company's provider of secretarial and corporate compliance services. The Board thanks Melanie for her valuable contributions to the Company during her tenure as Company Secretary.

Ms. Naomi Lawrie is a corporate lawyer and company secretary with more than 20 years of experience, particularly with health and technology companies.

Ms. Lawrie is responsible for communication with the ASX in relation to listing rule matters for the purpose of ASX Listing Rule 12.6.

**-ENDS-**

**For enquiries, please contact**

Dr Paul Gavin  
Chief Executive Officer  
Avecho Biotechnology Limited  
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

**About Avecho**

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's lead asset is a proprietary cannabidiol ("CBD") TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia.

See more here - [avecho.com.au](https://avecho.com.au)